Patents by Inventor Aymen Al-Shamkhani
Aymen Al-Shamkhani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11780929Abstract: The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof.Type: GrantFiled: April 20, 2021Date of Patent: October 10, 2023Assignee: Cancer Research Technology LimitedInventors: Aymen Al-Shamkhani, Hak Tak Claude Chan, Mark Steven Cragg, Ruth Rosemary French, Martin John Glennie, Jane Elizabeth Willoughby
-
Publication number: 20230192845Abstract: Provided is a CD96-binding agent, wherein the agent is capable of stimulating activation and/or proliferation of T cells upon binding to CD96. Also provided are isolated nucleic acids and cells that produce the agent and uses thereof.Type: ApplicationFiled: August 10, 2018Publication date: June 22, 2023Applicants: BLINK BIOMEDICAL SAS, TALIX THERAPEUTICS NVInventors: Florence Renart-Depontieu, Sachiko Takami, Germain Margall-Ducos, Nicola Beltraminel-Li, Pierre Garrone, Anne Rogel, Aymen Al-Shamkhani, Xavier Preville
-
Publication number: 20230058227Abstract: Described is the sequential administration of first a Treg depleting antibody mole-cute selected from antibody molecules, such as an antibody molecule binding specifically to target belonging to the tumour necrosis factor receptor superfamily (TNFRSF), such as a Treg depleting anti-4-1 BB antibody or a Treg depleting OX-40 antibody, and then an immunostimulatory antibody molecule, such as an immunostimulatory anti-4-1 BB anti-body or an immunostimulatory OX-40 antibody, for use in the treatment of cancer. De-scribed are also novel anti-4-1 BB antibodies and novel OX-40 antibodies that may be used in such sequential administration.Type: ApplicationFiled: August 11, 2022Publication date: February 23, 2023Inventors: Björn FRENDÉUS, Linda MÅRTENSSON, Monika SEMMRICH, Ingrid TEIGE, Stephen BEERS, Aymen AL-SHAMKHANI, Juliet GRAY, Martin GLENNIE
-
Patent number: 11447549Abstract: Described is the sequential administration of first a Treg depleting antibody molecule selected from antibody molecules, such as an antibody molecule binding specifically to target belonging to the tumour necrosis factor receptor superfamily (TNFRSF), such as a Treg depleting anti-4-1 BB antibody or a Treg depleting OX-40 antibody, and then an immunostimulatory antibody molecule, such as an immunostimulatory anti-4-1 BB anti-body or an immunostimulatory OX-40 antibody, for use in the treatment of cancer. Described are also novel anti-4-1 BB antibodies and novel OX-40 antibodies that may be used in such sequential administration.Type: GrantFiled: July 26, 2018Date of Patent: September 20, 2022Assignee: CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Björn Frendéus, Linda Mårtensson, Monika Semmrich, Ingrid Teige, Stephen Beers, Aymen Al-Shamkhani, Juliet Gray, Martin Glennie
-
Publication number: 20220213207Abstract: The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof.Type: ApplicationFiled: April 20, 2021Publication date: July 7, 2022Applicant: Cancer Research Technology LimitedInventors: Aymen Al-Shamkhani, Hak Tak Claude Chan, Mark Steven Cragg, Ruth Rosemary French, Martin John Glennie, Jane Elizabeth Willoughby
-
Publication number: 20210317222Abstract: The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof.Type: ApplicationFiled: April 20, 2021Publication date: October 14, 2021Applicant: Cancer Research Technology LimitedInventors: Aymen Al-Shamkhani, Hak Tak Claude Chan, Mark Steven Cragg, Ruth Rosemary French, Martin John Glennie, Jane Elizabeth Willoughby
-
Patent number: 11001638Abstract: The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof.Type: GrantFiled: November 4, 2016Date of Patent: May 11, 2021Assignee: Cancer Research Technology LimitedInventors: Aymen Al-Shamkhani, Hak Tak Claude Chan, Mark Steven Cragg, Ruth Rosemary French, Martin John Glennie, Jane Elizabeth Willoughby
-
Publication number: 20200207855Abstract: Described is the sequential administration of first a Treg depleting antibody molecule selected from antibody molecules, such as an antibody molecule binding specifically to target belonging to the tumour necrosis factor receptor superfamily (TNFRSF), such as a Treg depleting anti-4-1 BB antibody or a Treg depleting OX-40 antibody, and then an immunostimulatory antibody molecule, such as an immunostimulatory anti-4-1 BB anti-body or an immunostimulatory OX-40 antibody, for use in the treatment of cancer. Described are also novel anti-4-1 BB antibodies and novel OX-40 antibodies that may be used in such sequential administration.Type: ApplicationFiled: July 26, 2018Publication date: July 2, 2020Inventors: Björn FRENDÉUS, Linda MÅRTENSSON, Monika SEMMRICH, Ingrid TEIGE, Stephen BEERS, Aymen AL-SHAMKHANI, Juliet GRAY, Martin GLENNIE
-
Publication number: 20200017594Abstract: The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof.Type: ApplicationFiled: November 4, 2016Publication date: January 16, 2020Applicant: Cancer Research Technology LimitedInventors: Aymen Al-Shamkhani, Hak Tak Claude Chan, Mark Steven Cragg, Ruth Rosemary French, Martin John Glennie, Jane Elizabeth Willoughby
-
Publication number: 20190169306Abstract: The disclosure relates to a method of treatment or prevention of B-cell related disease in a subject comprising the administration of a binding molecule capable of binding to a B-cell and promoting killing of the B-cell; and an immunostimulatory agent arranged to stimulate effector lymphocytes, such as NK and/or T cells. Additionally, an anti-CD27 binding agent for use in a combination therapy with an anti-CD20 binding agent for the treatment or prevention of B-cell related disease in a subject. The disclosure also relates to a method of treatment or prevention of cancer in a subject comprising the administration of a cancer-cell-depleting binding agent capable of binding to the cancer cell and promoting killing of the cancer cell; and an immunostimulatory agent arranged to stimulate NK and/or T-cell activation. Additionally, an anti-CD27 binding agent for use in a combination therapy with a cancer-cell-depleting binding agent for the treatment or prevention of cancer in a subject.Type: ApplicationFiled: July 28, 2017Publication date: June 6, 2019Inventors: Martin John Glennie, Aymen Al-Shamkhani, Mark Steven Cragg, Sean Hua Lim
-
Publication number: 20180327504Abstract: The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof.Type: ApplicationFiled: November 4, 2016Publication date: November 15, 2018Applicant: Cancer Research Technology LimitedInventors: Aymen Al-Shamkhani, Hak Tak Claude Chan, Mark Steven Cragg, Ruth Rosemary French, Martin John Glennie, Jane Elizabeth Willoughby
-
Publication number: 20180273631Abstract: Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-1BB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.Type: ApplicationFiled: March 23, 2018Publication date: September 27, 2018Inventors: Martin John GLENNIE, Alison Louise TUTT, Aymen AL-SHAMKHANI
-
Patent number: 9926374Abstract: Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-1BB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.Type: GrantFiled: December 18, 2015Date of Patent: March 27, 2018Assignee: UNIVERSITY OF SOUTHAMPTONInventors: Martin John Glennie, Alison Louise Tutt, Aymen Al-Shamkhani
-
Patent number: 9248183Abstract: Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-1BB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.Type: GrantFiled: May 30, 2013Date of Patent: February 2, 2016Assignee: University of SouthamptonInventors: Martin John Glennie, Alison Louise Tutt, Aymen Al-Shamkhani
-
Publication number: 20130336976Abstract: Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-1BB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.Type: ApplicationFiled: May 30, 2013Publication date: December 19, 2013Inventors: Martin John Glennie, Alison Louise Tutt, Aymen Al-Shamkhani
-
Patent number: 8481029Abstract: Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-IBB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.Type: GrantFiled: October 18, 2007Date of Patent: July 9, 2013Assignee: University of SouthamptonInventors: Martin John Glennie, Alison Louise Tutt, Aymen Al-Shamkhani
-
Publication number: 20110033449Abstract: Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-IBB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.Type: ApplicationFiled: October 18, 2007Publication date: February 10, 2011Inventors: Martin John Glennie, Alison Louise Tutt, Aymen Al-Shamkhani
-
Publication number: 20040047873Abstract: The invention provides a protein framework which allows active polypeptides e.g. ligands or antigens to be displayed at increased concentration. The inventors show that the lectin binding domains of collectins can be replaced by a polypeptide of interest and that polypeptide can be multimerised by the framework of the collectin and as a result displayed in greater number on a single structure. The inventors show that the activity of polypeptides such as those of the TNF superfamily are significantly enhanced when displayed in this way.Type: ApplicationFiled: October 10, 2003Publication date: March 11, 2004Inventors: Aymen Al- Shamkhani, Martin Glennie
-
Patent number: 5622718Abstract: The invention is an alginate-bioactive agent conjugate connected via an acid labile biodegradable spacer linkage. The conjugate is effective for delivering bioactive agents to targets existing in low-pH environments, either at the target surface or in the target interior.Type: GrantFiled: April 28, 1995Date of Patent: April 22, 1997Assignee: Keele UniversityInventors: Aymen Al-Shamkhani, Ruth Duncan